Lunan Pharmaceutical ranks 32nd in national pharmaceutical industry revenue list

The 43rd National Pharmaceutical Industry Information Annual Conference opened in Beijing on July 11-12, releasing the 2025 Top 100 Enterprises by Main Business Income in China’s Pharmaceutical Industry. Lunan Pharmaceutical Group secured the 32nd place, winning two national excellent case awards for R&D pipeline and corporate social responsibility.

Zhang Guimin, Party Secretary and General Manager of Lunan Pharmaceutical, delivered a speech at the Chinese Medicine High-quality Development Forum, interpreting the balanced philosophical logic of traditional Chinese medicine. He also participated in special seminars on Chinese medicine industrial innovation and AI-enabled pharmaceutical research. Facing the 15th Five-Year Plan period, biomedicine has been positioned as a strategic emerging pillar industry nationwide.

Adhering to innovation-driven development, Lunan Pharmaceutical will continuously boost R&D investment and achievement transformation, align with national health strategies, and cooperate with industry peers to contribute to the high-quality growth of national medicine and the Healthy China Initiative.

Editor：韩蒙蒙